Research programme: LDL receptor gene transcription regulators - Amgen
Alternative Names: LDL receptor gene transcription regulators research programme - AmgenLatest Information Update: 04 Feb 2008
At a glance
- Originator Amgen; University of Texas Southwestern Medical Center
- Class
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 17 Dec 2003 This programme is still in active development
- 10 Mar 1999 Preclinical development for Hypercholesterolaemia in USA (PO)